Login / Signup

The use of cytapheresis in the treatment of infectious diseases.

Andrew P NorganJustin E JuskewitchBobbi S PrittJeffrey Lawrence Winters
Published in: Journal of clinical apheresis (2018)
Cytapheresis (removal of cellular blood components) has been employed for treatment of infectious diseases since the 1960s. Techniques have included thrombocytapheresis (buffy coat apheresis) for loiasis, erythrocytapheresis for malaria and babesiosis, and leukocytapheresis for pertussis-associated lymphocytosis. Published data on these applications is largely limited to case level data and small observational studies; as such, recommendations for or against the use of cytapheresis in the treatment of infections have been extrapolated from these limited (and at times flawed) data sets. Consequently, utilization of cytapheresis in many instances is not uniform between institutions, and typically occurs at the discretion of treating medical teams. This review revisits the existing literature on the use of cytapheresis in the treatment of four infections (loasis, malaria, babesiosis, and pertussis) and examines the rationale underlying current treatment recommendations concerning its use.
Keyphrases
  • infectious diseases
  • healthcare
  • electronic health record
  • randomized controlled trial
  • machine learning
  • big data
  • replacement therapy
  • artificial intelligence
  • smoking cessation